Bristol Myers Squibb (BMY) Cash from Investing Activities (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Cash from Investing Activities data on file, last reported at -$131.0 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$131.0 million, up 73.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.8 billion (down 68.56% YoY), and the FY2025 annual result was -$4.1 billion, up 80.65% from the prior year.
• Cash from Investing Activities advanced to -$131.0 million in Q1 2026 per BMY's latest filing, from -$1.5 billion in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $1.2 billion in Q4 2022 and troughed at -$19.6 billion in Q1 2024.
• A 5-year average of -$1.7 billion and a median of -$410.0 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities surged 202.49% in 2022, then slumped 9241.9% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $1.2 billion in 2022, then tumbled by 210.96% to -$1.3 billion in 2023, then jumped by 85.44% to -$196.0 million in 2024, then slumped by 643.88% to -$1.5 billion in 2025, then jumped by 91.02% to -$131.0 million in 2026.
• Business Quant data shows BMY's Cash from Investing Activities at -$131.0 million in Q1 2026, -$1.5 billion in Q4 2025, and -$1.7 billion in Q3 2025.